Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing biopharmaceutical research companies, generally supports the intent of the Draft Guidance but expresses concerns that it may impose new, non-binding CGMP requirements or create unnecessary administrative burdens. They request clarifications to ensure the guidance remains voluntary, respects existing Quality Management Systems (QMS), and allows for risk-based discretion in responding to FDA 483 observations.